Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Enrichment for Cases of African-American Patients with Pathogenic TTR V142I Variant in the TOPCAT Trial

Nikolaos Papoutsidakis, Neeru Gandotra, View ORCID ProfileEdward Miller, View ORCID ProfileMichael F. Murray, View ORCID ProfileCurt Scharfe, View ORCID ProfileDaniel Jacoby
doi: https://doi.org/10.1101/2020.10.14.20201046
Nikolaos Papoutsidakis
1Department of Internal Medicine, Cardiovascular Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neeru Gandotra
2Department of Genetics, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Miller
1Department of Internal Medicine, Cardiovascular Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edward Miller
Michael F. Murray
2Department of Genetics, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael F. Murray
Curt Scharfe
2Department of Genetics, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Curt Scharfe
  • For correspondence: curt.scharfe@yale.edu
Daniel Jacoby
1Department of Internal Medicine, Cardiovascular Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Jacoby
  • For correspondence: curt.scharfe@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Transthyretin cardiac amyloidosis (ATTR-CA) is a treatable cause of heart failure with a hereditary form that disproportionally affects patients of West African ancestry. The clinical management of ATTR-CA has dramatically changed in the past five years, with rapidly evolving diagnostic approaches and life-prolonging therapies. The TTR variant c.424G>A, p.V142I (aka V122I) is pathogenic and occurs in 3-4% of individuals of West African ancestry. Despite its high frequency, V142I ATTR-CA is often unrecognized due to variable clinical penetrance, limited knowledge, and lack of inexpensive non-invasive diagnostic tests. Currently unknown is which TTR V142I carriers will progress to heart failure and at what age. Here we studied the prevalence of TTR V142I among a random cohort of African-American patients enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT). Three of the 26 HFpEF patients (11.5%) studied carried the pathogenic TTR V142I variant. While we cannot conclude at this point that TTR V142I was the underlying cause of the clinical phenotype in these patients, our results suggest that rapid TTR V142I genotyping, in combination with heart imaging, could have immediate clinical utility for identifying under-/mis-diagnosed HFpEF patients.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

N.a.

Funding Statement

This work was in parts supported by institutional funds at Yale University and a Connecticut Innovations Biopipeline program award (CS).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was overseen by the institutional review board at Yale University.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data referred to in the manuscript are provided in Table 1.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted October 16, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Enrichment for Cases of African-American Patients with Pathogenic TTR V142I Variant in the TOPCAT Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Enrichment for Cases of African-American Patients with Pathogenic TTR V142I Variant in the TOPCAT Trial
Nikolaos Papoutsidakis, Neeru Gandotra, Edward Miller, Michael F. Murray, Curt Scharfe, Daniel Jacoby
medRxiv 2020.10.14.20201046; doi: https://doi.org/10.1101/2020.10.14.20201046
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Enrichment for Cases of African-American Patients with Pathogenic TTR V142I Variant in the TOPCAT Trial
Nikolaos Papoutsidakis, Neeru Gandotra, Edward Miller, Michael F. Murray, Curt Scharfe, Daniel Jacoby
medRxiv 2020.10.14.20201046; doi: https://doi.org/10.1101/2020.10.14.20201046

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5218)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5820)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1994)
  • Radiology and Imaging (344)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)